Bayer Healthcare Drug Patent Portfolio

Bayer Healthcare owns 3 orange book drugs protected by 29 US patents Given below is the list of Bayer Healthcare's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11168058 Manufacture of a crystalline pharmaceutical product 27 Feb, 2038
Active
US10045991 Methods of treating pediatric cancers 04 Apr, 2037
Active
US10137127 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide 04 Apr, 2037
Active
US10668072 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide 04 Apr, 2037
Active
US11191766 Methods of treating pediatric cancers 04 Apr, 2037
Active
US11484535 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide 04 Apr, 2037
Active
US10799505 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate 15 Aug, 2036
Active
US10010530 Carboxamide derivative and its diastereomers in stable crystalline form 28 Jan, 2036
Active
US10383853 Carboxamide derivative and its diastereomers in stable crystalline form 28 Jan, 2036
Active
US10835515 Carboxamide derivative and its diastereomers in stable crystalline form 28 Jan, 2036
Active
US10172861 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate 16 Nov, 2035
Active
US9782414 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate 16 Nov, 2035
Active
US8975254 Androgen receptor modulating compounds 25 Mar, 2033
Active
US10383876 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts 29 Mar, 2032
Active
US9636344 Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts 29 Mar, 2032
Active
US10711013 Androgen receptor modulating compounds 27 Oct, 2030
Active
US11046713 Androgen receptor modulating compounds 27 Oct, 2030
Active
US9657003 Androgen receptor modulating compounds 27 Oct, 2030
Active
US8513263 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors 23 Dec, 2029
Active
US8466283 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis 22 Oct, 2029
Active
USRE46856 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis 22 Oct, 2029
Active
US10005783 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds 21 Oct, 2029
Active
US10047097 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds 21 Oct, 2029
Active
US10774085 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds 21 Oct, 2029
Active
US8865698 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds 21 Oct, 2029
Active
US9127013 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds 21 Oct, 2029
Active
US9447104 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds 21 Oct, 2029
Active
US9676783 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds 21 Oct, 2029
Active
US7511041 Fused azole-pyrimidine derivatives 13 May, 2024 Expired


Given below is the list of recent legal activities going on the following drug patents of Bayer Healthcare.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 10 Apr, 2024 US10813936
Payment of Maintenance Fee, 4th Year, Large Entity 27 Mar, 2024 US10799505
Letter from FDA or Dept of Agriculture re PTE application 18 Mar, 2024 US7511041
Payment of Maintenance Fee, 8th Year, Large Entity 06 Mar, 2024 US9447104
Payment of Maintenance Fee, 4th Year, Large Entity 28 Feb, 2024 US10774085
Payment of Maintenance Fee, 4th Year, Large Entity 04 Jan, 2024 US10711013
Notice of Final Determination -Eligible 07 Dec, 2023 US7511041
Payment of Maintenance Fee, 4th Year, Large Entity 15 Nov, 2023 US10668072
FDA Final Eligibility Letter 14 Nov, 2023 US7511041
Payment of Maintenance Fee, 8th Year, Large Entity 22 Feb, 2023 US9127013
Payment of Maintenance Fee, 4th Year, Large Entity 15 Feb, 2023 US10383853
Patent Term Extension Certificate 15 Feb, 2023 US8975254
transaction for FDA Determination of Regulatory Review Period 14 Feb, 2023 US7511041
Payment of Maintenance Fee, 4th Year, Large Entity 08 Feb, 2023 US10383876
transaction for FDA Determination of Regulatory Review Period 18 Jan, 2023 US7511041


Bayer Healthcare Drug Patents' Oppositions Filed in EPO

Bayer Healthcare drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 17, 2023, by Hamm&Wittkopp Patentanwälte Partmbb. This opposition was filed on patent number EP16704029A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16704029A Feb, 2023 Hamm&Wittkopp Patentanwälte PartmbB Granted and Under Opposition


Bayer Healthcare's Family Patents

Bayer Healthcare drugs have patent protection in a total of 56 countries. It's US patent count contributes only to 13.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Bayer Healthcare Drug List

Given below is the complete list of Bayer Healthcare's drugs and the patents protecting them.


1. Aliqopa

Aliqopa is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10383876 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts 29 Mar, 2032
(7 years from now)
Active
US9636344 Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts 29 Mar, 2032
(7 years from now)
Active
US8466283 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis 22 Oct, 2029
(5 years from now)
Active
USRE46856 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis 22 Oct, 2029
(5 years from now)
Active
US7511041 Fused azole-pyrimidine derivatives 13 May, 2024
(4 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aliqopa's drug page


2. Nubeqa

Nubeqa is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11168058 Manufacture of a crystalline pharmaceutical product 27 Feb, 2038
(13 years from now)
Active
US10010530 Carboxamide derivative and its diastereomers in stable crystalline form 28 Jan, 2036
(11 years from now)
Active
US10383853 Carboxamide derivative and its diastereomers in stable crystalline form 28 Jan, 2036
(11 years from now)
Active
US10835515 Carboxamide derivative and its diastereomers in stable crystalline form 28 Jan, 2036
(11 years from now)
Active
US8975254 Androgen receptor modulating compounds 25 Mar, 2033
(8 years from now)
Active
US10711013 Androgen receptor modulating compounds 27 Oct, 2030
(6 years from now)
Active
US11046713 Androgen receptor modulating compounds 27 Oct, 2030
(6 years from now)
Active
US9657003 Androgen receptor modulating compounds 27 Oct, 2030
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nubeqa's drug page


3. Vitrakvi

Vitrakvi is protected by 16 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10045991 Methods of treating pediatric cancers 04 Apr, 2037
(12 years from now)
Active
US10137127 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide 04 Apr, 2037
(12 years from now)
Active
US10668072 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide 04 Apr, 2037
(12 years from now)
Active
US11191766 Methods of treating pediatric cancers 04 Apr, 2037
(12 years from now)
Active
US11484535 Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide 04 Apr, 2037
(12 years from now)
Active
US10799505 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate 15 Aug, 2036
(11 years from now)
Active
US10172861 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate 16 Nov, 2035
(11 years from now)
Active
US9782414 Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate 16 Nov, 2035
(11 years from now)
Active
US8513263 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors 23 Dec, 2029
(5 years from now)
Active
US10005783 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds 21 Oct, 2029
(5 years from now)
Active
US10047097 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds 21 Oct, 2029
(5 years from now)
Active
US10774085 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds 21 Oct, 2029
(5 years from now)
Active
US8865698 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds 21 Oct, 2029
(5 years from now)
Active
US9127013 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds 21 Oct, 2029
(5 years from now)
Active
US9447104 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds 21 Oct, 2029
(5 years from now)
Active
US9676783 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds 21 Oct, 2029
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitrakvi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List